

February 10, 2021

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b> <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b> <b>Company Code No. 524804</b>
--	--

Dear Sir,

**Sub: Outcome of Board Meeting held on February 10, 2021.**

The Board of Directors of the Company at its meeting held today, February 10, 2021, has, inter alia, considered and approved:-

1. the Un-audited Financial Results of the Company for the Third Quarter and nine months period ended December 31, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.
2. a Third Interim Dividend @ 150% i.e Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21. The Company has fixed **February 23, 2021** as the **Record Date** for the purpose of payment of Third Interim Dividend and the same will be paid on or before **March 4, 2021**.

We also enclose a copy of the Press Release on Un-audited Financial Results of the Company for the Third Quarter and nine months period ended December 31, 2020.

The Board meeting commenced at 4.00 p.m. and concluded at 6.40 p.m.

Please take the information on record.

Thanking you,

Yours faithfully,  
For **AUROBINDO PHARMA LIMITED**

  
B. Adi Reddy  
Company Secretary



Enclosures: as above,